Early Phase II Data Shows Alnylam RSV Drug to Be Safe, Well-Tolerated | GenomeWeb

Alnylam Pharmaceuticals this week announced that preliminary data from a phase II trial of its siRNA-based respiratory syncytial virus treatment ALN-RSV01 has shown the drug to be safe and tolerable, the primary endpoints of the study.

Detailed efficacy data, however, were not available since the trial was not designed to measure such outcomes, the company added.

In the trial, 24 lung-transplant patients with confirmed RSV infections were randomized to receive inhaled ALN-RSV01 or placebo once daily for three consecutive days, according to the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.